View this email in your browser

Dear <<First Name (optional)>>,

As the pandemic continues to rage across the world, the urgent need for solutions to support increased global supply of COVID-19 medicines, vaccines and other health technologies only grows.

Last week the World Trade Organization (WTO) Director-General, Dr Ngozi Okonjo-Iweala, called on governments to move forward with negotiations on the landmark TRIPS waiver proposal initially made by India and South Africa last year.

100 countries have declared their public support for the WTO waiver on patents and other intellectual property to help increase supplies of urgently needed medical tools and to save lives. But the US, EU, Switzerland, Canada, Japan, Australia and Brazil are still blocking this proposal.

Today the negotiations continue at the WTO. After an encouraging statement from the US, we call on all opposing countries to stop blocking the waiver and allow the #NoCovidMonopolies movement to move ahead swiftly to help save lives.

Please help us and share our message on social media:

Future medicines already under threat

Today there are several promising medicines in development for COVID-19. These new treatments could be a critical part of the ongoing response to the pandemic.

But pharmaceutical corporations have already filed patents on several of these medicines.

The TRIPS waiver could break the companies’ stranglehold on these future medicines and open up access to all who may need them.

At a time when more than three million lives have been lost to COVID-19 around the world, we urge countries not to cave into pressure from the pharmaceutical industry and support the waiver to overcome COVID-19 monopolies.

Share our message now – so that countries stop blocking this lifesaving proposal!

Thank you!

The Access Campaign team

← Find out more about how we work

2021 MSF Access Campaign, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp